Viva Biotech Ltd is a Shanghai-based contract research organization (CRO) providing integrated early-stage drug discovery services to the global pharmaceutical and biotechnology industries. The company’s offerings span target identification, fragment-based drug discovery, structure-based design, medicinal chemistry, high-throughput screening, in vitro ADME/Tox assays and antibody discovery. Viva Biotech leverages a proprietary fragment library and in-house structural biology capabilities to support hit identification and lead optimization across a broad range of therapeutic modalities.
With an emphasis on accelerating preclinical programs, the company combines X-ray crystallography, high-content cell-based assays and comprehensive pharmacokinetic profiling to help clients progress candidates from hit to lead. Viva Biotech’s platform is designed to be highly modular, enabling collaborations on small molecules, peptides and biologics. Over the years, the organization has formed research partnerships with a diverse roster of international biopharma firms, reflecting its adaptability across multiple target classes and therapeutic areas.
Headquartered in Shanghai, Viva Biotech maintains additional research facilities and offices in Wuhan and Suzhou, serving customers across North America, Europe and Asia. Its management team comprises industry veterans in chemistry, biology and drug development, whose collective expertise underpins the company’s mission to streamline discovery timelines and deliver actionable preclinical data. By offering end-to-end services under one roof, Viva Biotech positions itself as a one-stop solution for early discovery challenges.
AI Generated. May Contain Errors.
Free VBIZF Stock Alerts